Ruti Aga's Six-Year Ban: How a Forged Prescription Ended a Stellar Career

Ruti Aga's name is remembered for the moment she won the 2026 Tokyo Marathon. But the news that broke last Thursday tells a completely different story. The Athletics Integrity Unit (AIU) announced that the 32-year-old Ethiopian runner has been banned for six years for producing a fake prescription. The ban is effective from September 10, the day she was provisionally suspended. The arithmetic is straightforward: two years for the presence of the substance, and four years for tampering. But the real story of this case is more complex than the prescription itself. It is the story of the system that surrounds these runners — a network where medical support is informal, and the cost of risk is often a career. The first thing that immediately draws attention in this case is the half marathon she won in China in March. But no time for that race is given in the report. No splits, no field strength. When you want to assess performance, this information is essential. But if you try to infer form from the win alone, that would be a wrong conclusion. The facts are these: a half marathon held in China in March, which she won, and after which her doping test came back positive. This race was likely a World Athletics Label road race, where elite women compete and AIU testing takes place. But the real question is: how did she win this race, and what happened after that victory? The substance found in the positive test was methylprednisolone. Many media reports described it as a "prohibited steroid," which is technically incorrect. It is a glucocorticoid, falling under class S9 of the WADA Prohibited List. This class is prohibited only in-competition, and only by injection, oral, or rectal routes. This is a crucial legal nuance. It means that if an athlete is given an injection for a knee injury a few days before a competition, it is completely legal — provided the drug residue is not present during the competition. In this case, Aga cited a knee injury. This is a common injury among marathon runners, especially those who train at high volume over long distances. Methylprednisolone injection for knee inflammation is a standard sports-medicine treatment. But there was a problem: she had no real documentation of this treatment. And when asked for evidence, she produced a fake prescription. What emerged in the AIU investigation is startling. The prescription was issued by a clinic that did not exist. The "doctor" who wrote it was a family member with no medical registration. He claimed to have used "an old prescription pad from a former workplace," but that clinic explicitly disowned the claim. These are three independent verification failures. This is not just negligence; it is a sign of a system where athletes operate without a credentialed team physician. An athlete with real documentation of a knee injection would either apply for a TUE (Therapeutic Use Exemption) or follow WADA's route-specific washout rules. Nothing of the sort happened here. Instead, a fake document was created. This case is not just an athlete's mistake. It points to a broader problem. In East African road running, especially in the marathon, medical support is often informal. Many athletes work with coaches and agents who have no medical training. When injury strikes, the easiest solution is to mask the pain, because appearance fees are significant. Glucocorticoids are the cheapest and most readily available tool. But when a doping test occurs, that same tool becomes a major problem. Aga's case is a clear example. She is 32, and the six-year ban will keep her out of the sport until she is 38. Competition in Ethiopian women's marathon is so deep that a 38-year-old with a doping record is virtually unselectable for the national team. This ban is effectively the end of her career. But a question arises: is this punishment proportionate? A six-year ban for a substance with no proven endurance benefit might surprise some. The AIU's approach is strict, and this case is an example of that strictness. But some critics might see it as unequal enforcement against African road runners. The truth is that forging a prescription is a serious offence. It is not just a technical violation but an attempt to mislead an investigation. The AIU took it seriously, and this ban is an expression of that. There is another layer to Aga's career that must be added to this debate. She won the 2026 Tokyo Marathon and finished second three times at World Marathon Majors. These were the peaks of her career. The scope of the ban does not explicitly state whether her past results will be annulled. Typically, the AIU only annuls results from the competition where the sample was collected, unless there is evidence of earlier use. This means her 2026 Tokyo win and other major performances are likely to stand. But her commercial standing is now split in two: on one hand, she is a genuinely elite marathoner; on the other, she is a banned athlete whom sponsors may now consider risky. There is another aspect of this case that cannot be ignored. The incident occurred at a label race in China, where East African runners are common. These races offer attractive appearance fees and are a high-yield testing ground for the AIU. Here, the appearance-fee economy and the testing economy collide. Aga's case is a result of that collision. It is possible that more similar cases will emerge in the future, because the same informal medical network serves many athletes. There is also the question of whether anyone else is responsible in this case. The AIU report names only the family member. But was the agent or management investigated? That is unclear. It is also possible that someone advised her to create the fake document. In such cases, the network around the athlete often plays a crucial role. One thing is clear from this whole episode: the integrity framework in athletics is getting stronger, but the medical support framework is not. Until athletes have access to proper medical advice and resources, such cases will continue to surface. Aga's case is a warning. It is not just an athlete's mistake but the failure of a system that does not provide adequate support to its athletes. What next? Aga has the option to appeal to CAS, but overturning the evidence of a fake document will be difficult. The Ethiopian athletics federation's response has not yet been made public. And the most important question is: will the athletics world learn any lesson from this case? Will athletes get better access to medical support? Or will this be just another case that makes headlines and is then forgotten? If I may say something from my 32 years of experience, it is that such cases often expose the weaknesses of the system. When an athlete has a knee injury, they need proper treatment, not a fake prescription. When they are called for a doping test, they need proper documentation, not an excuse. But if the system does not provide all this, they may go down the wrong path. This case is not just about Ruti Aga, but about all athletes caught in similar circumstances. One small ask: athletics federations should ensure medical and legal support for athletes. A mechanism should be created where athletes can treat their injuries without fear and comply with doping rules. This is not just a moral obligation but also necessary for the integrity of the sport.